Transcriptionally targeted gene therapy

Current Topics in Microbiology and Immunology

Volumn 213 III, Issue , 1996, Pages 19-25

  Hart, I R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELANIN;

BIOSYNTHESIS; DRUG TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0029933063     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80071-9_2     Document Type: Review

References (27)

1. Carrell S, Johnson JP (1993) Immunologic recognition of malignant melanoma by autologous T lymphocytes Curr Opin Oncol 5: 383-389
2. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumour immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71: 1093-1102
3. Crowley NJ, Seigler HF (1993) Possibilities of immunotherapy and gene therapy for malignant melonoma Semin Surg Oncol 9: 273-278
4. Culver KW, Blaese RM (1994) Gene therapy for cancer. Trends 10 174-178
5. Gansbacher B, Houghton A, Livingston P, Minasian L, Rosenthal F, Gilboa E, Golde D, Oettgen H, Steffens T, Yang SY, Wong G (1992) Clinical protocol: a pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melonoma. Hum Gene Ther 3: 677-690
6. Huber BE, Richards CA, Krenitsky TA (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy Proc Natl Acad Sci USA 88: 8039-8043
7. Jackson IJ, Chambers DM, Budd PS, Johnson R (1991) The tyrosinase related protein-1 gene has a structure and promoter sequence very different from tyrosinase. Nucleic Acids Res 19: 3798-3804
8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994a) A cell-cycle regulator potentially involved in genesis of many tumor types Science 264: 436-440
9. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994b) Analysis of the p16 gene (cdkn2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8: 22-26
10. Kluppel M, Beermann F, Puppert S, Schmid E, Hummler E, Schutz G (1991) The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. Proc Natl Acad Sci USA 88 3777-3781
11. Korner A, Pawalek J (1982) Mammalian tyrosinase catalyses three reactions in the biosynthesis of melanin. Science 217: 1163-1165
12. Nabel GJ, Nabel EG, Yang Z-Y, Fox SA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans, Proc Natl Acad Sci USA 90 11307-11311
13. Oldfield EH, Ram Z, Culver KW, Blaese RM, De Vroom HL, Anderson WF (1993) Clinical protocol: gene therapy for the treatment of brain kinase gene and intravenous ganciclovir Hum Gene Ther 4: 39-69
14. Pardoll DM (1994) Tumour antigens: a new took for the 1990s. News and views Nature 369: 357-358
15. Plautz GE, Yang ZY, Wu BY, Gao X, Huong L, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90: 4645-4649
16. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral mediated gene transfer for the treatment of brain tumors in rats Cancer Res 53: 83-88
17. + cells by B7-transfected melanoma cells Science 259: 368-370
18. Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJA (1992) Second tyrosinase related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J 11: 519-526
19. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254. 1643-1647
20. Vile RG, Hart IR(1993a) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 53. 962-967
21. Vile RG, Hart IR (1993b) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoural injection of DNA. Cancer Res 53: 3860-3864
22. Vile RG, Hart IR (1994) Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann Oncol 5 Suppl 4: S59-S65
23. Vile RG, Russell SJ (1994) Gene transfer technologies for the gene therapy of cancer. Gene Ther 1 88-98
24. Vile RG, Miller N, Hart IR(1994a) Retroviral vectors for the gene therapy of malignant melanoma Gene Ther 1: 307-316
25. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994b) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Res 54: 6228-6234
26. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA (1975) Human serum lyses RNA tumour viruses. Nature 257: 612-614
27. Yavuzer U, Coding CR (1994) Melanocyte-specific gene expression, role of repression and identification of a melanocyte-specific factor, MSF. Mol Cell Biol 14: 3494-3508